Tymlos Injection, Solution
Product Images NDC 70539-001

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Tymlos (NDC 70539-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Radius Health, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tym00 0000 01

A line graph depicting abaloparatide concentration (pg/mL) over time (hours). The graph shows a rapid increase to peak concentration shortly after time zero, followed by a gradual decline approaching zero concentration by 24 hours. Error bars are present indicating variability at each time point.*

FDA Label Image

Tym00 0000 02

A line graph showing patient nonvertebral fracture incidence (%) over study months (0 to 25). It compares four groups: Placebo (0-18 months) and Alendronate (19-25 months), TYMLOS (abaloparatide) 0-18 months and Alendronate 19-25 months. A vertical dashed line marks the start of Alendronate monotherapy at 19 months. The graph illustrates lower fracture incidence for TYMLOS vs. Placebo before month 19 and progression after switching to Alendronate.*

FDA Label Image

Tym00 0000 03

An instructional illustration showing parts of the TYMLOS pen for subcutaneous injection. The front view (Figure A) identifies the pen cap, cartridge holder, cartridge with label, dose display window, dose knob, and green injection button. The rear view (Figure B) shows the lot and expiration date on the cartridge label.*

FDA Label Image

Tym00 0000 04

An instructional diagram labeled 'Figure C' showing the parts of a pen needle for use with the Tymlos pen. The components include the outer pen needle cap, inner pen needle cap, pen needle, and protective paper with needle specifications. The image clarifies that the pen needle is not included with the Tymlos pen.*

FDA Label Image

Tym00 0000 05

An instructional illustration labeled Figure D showing a hand removing the cap from a pen-style injection device. The image is part of a guide likely related to the use of the Tymlos (abaloparatide) injection solution.*

FDA Label Image

Tym00 0000 06

An instructional illustration labeled Figure E showing a hand holding a small needle or injector tip, with the thumb and fingers positioned to grip or attach the needle to another component. This image likely depicts part of the process for preparing or using an injection device.*

FDA Label Image

Tym00 0000 07

An instructional diagram labeled Figure F showing a person holding an injection pen device. The illustration demonstrates twisting the pen cap counterclockwise to remove it, with an inset circle emphasizing not to pull the cap straight off. This image likely relates to preparing a subcutaneous injection pen for use.*

FDA Label Image

Tym00 0000 08

Illustration from the Tymlos injection instructions showing the removal of the cap from the injection pen prior to subcutaneous administration. The image depicts fingers pulling the cap off the pen with an orange arrow indicating the direction of removal.*

FDA Label Image

Tym00 0000 09

Instructional diagram labeled 'Figure H' showing a hand holding a vial with an orange arrow indicating the direction of drawing liquid into a syringe needle, illustrating part of the injection preparation process for a subcutaneous solution.*

FDA Label Image

Tym00 0000 10

FDA Label Image

Tym00 0000 11

Illustration showing how to rotate the cap on a Tymlos (abaloparatide) 3.12 mg/1.56 mL injection cartridge prior to use. A hand is shown holding the cartridge with an arrow indicating the direction to turn the cap, demonstrating part of the subcutaneous injection preparation process.*

FDA Label Image

Tym00 0000 12

An instructional illustration labeled 'Figure J' showing two hands interacting with a prefilled injection pen. The left hand holds the pen vertically while the right hand's thumb is about to press a button or dose selector on the device, demonstrating use or dosage operation of an injection pen, likely related to the subcutaneous injection of Tymlos (abaloparatide).*

FDA Label Image

Tym00 0000 13

An instructional diagram labeled Figure K showing two hands holding a Tymlos injection pen. The pen is shown with a close-up of the needle tip covered by a protective cap, and an inset showing the dose window displaying the number zero, indicating the device is ready or has been used.*

FDA Label Image

Tym00 0000 14

An instructional illustration labeled Figure L showing a hand holding a prefilled subcutaneous injection device with a digital dose counter displaying the number 80. The illustration includes an orange curved arrow indicating a twisting motion at the device's cap or plunger end.*

FDA Label Image

Tym00 0000 15

An instructional diagram labeled Figure M showing the lower abdominal area, highlighting a shaded region around the navel. This likely indicates an injection site, consistent with subcutaneous administration guidance.*

FDA Label Image

Tym00 0000 16

An instructional illustration labeled Figure N showing a hand holding an injection pen horizontally. The image depicts the proper grip for administering a subcutaneous injection with the pen device, which is consistent with Tymlos (abaloparatide) injection usage.*

FDA Label Image

Tym00 0000 17

An instructional diagram labeled Figure O showing a hand holding a subcutaneous injection pen, identified as Tymlos injection. The hand grips the pen, with an arrow indicating the direction to press or turn a green ring at the pen's base, alongside a clock graphic showing a 10-second wait. The image visually demonstrates a step in preparing or using the Tymlos injection pen.*

FDA Label Image

Tym00 0000 18

An instructional diagram labeled Figure P showing the removal of the outer needle cap from a prefilled pen or syringe, with an arrow indicating the direction to pull the cap off.*

FDA Label Image

Tym00 0000 19

An instructional illustration labeled 'Figure Q' showing hands rotating the cap of a pen-style injection device more than 8 turns, indicated by an orange curved arrow. The image likely demonstrates a step for preparing or priming the injection pen for use.*

FDA Label Image

Tym00 0000 20

An instructional diagram labeled 'Figure R' showing hands holding a syringe and cap, with an orange arrow indicating the removal of the cap from the syringe tip for preparing an injection.*

FDA Label Image

Tym00 0000 21

An instructional illustration labeled Figure S showing a hand removing the cap from a pen-style injection device. An orange arrow indicates the direction to pull the cap off, revealing the needle end of the device.*

FDA Label Image

Tym00 0000 22

Tymlos (abaloparatide) injection label for a 3.12 mg/1.56 mL solution delivering 80 mcg per dose. The label instructs single-patient use, storage requirements including refrigeration before first use and room temperature after opening, and discard instructions. It shows product NDC 70539-001-01 and the labeler Radius Health, Inc.*

FDA Label Image

Tym00 0000 23

Tymlos 80 mcg per dose (abaloparatide) injection 3120 mcg/1.56 mL (2000 mcg/mL) solution for subcutaneous use, single patient use only, in a prefilled pen. The packaging label features dose and strength information, instructions that the pen delivers 30 subcutaneous doses, and notes that needles are not included. Labeler is Radius Health, Inc.*

FDA Label Image

Tym00 0000 24

Label for Tymlos (abaloparatide) injection, solution for subcutaneous use, 80 mcg per dose in 1.56 mL prefilled pen delivering 30 doses. The label includes storage instructions to keep refrigerated before first use and room temperature after first use, with a discard notice 30 days post opening. Manufactured by Radius Health, Inc.*

FDA Label Image

Tym00 0000 25

Tymlos (abaloparatide) injection 80 mcg per dose (3120 mcg/1.56 mL) subcutaneous injection solution. The orange and purple carton label states it is a single-patient use, sterile, prescription drug by Radius Health, Inc. Packaging includes 1 prefilled pen designed to deliver 30 subcutaneous doses. Marked as a sample, not for sale.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.